UY27689A1 - Nuevos derivados de tiazol como antagonistas del receptor npy - Google Patents
Nuevos derivados de tiazol como antagonistas del receptor npyInfo
- Publication number
- UY27689A1 UY27689A1 UY27689A UY27689A UY27689A1 UY 27689 A1 UY27689 A1 UY 27689A1 UY 27689 A UY27689 A UY 27689A UY 27689 A UY27689 A UY 27689A UY 27689 A1 UY27689 A1 UY 27689A1
- Authority
- UY
- Uruguay
- Prior art keywords
- tiazol
- npy
- antagonists
- receiver
- new derivatives
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos de fómula I así como sales y ésteres farmacéuticamente aceptables de los mismos, en donde R1 A R5, n, m y A tienen el significado dado en la reivindicación 1, se puede usar en la forma de preparaciones farmacéuticas para el tratamiento o prevención de artritis, enfermedades cardiovasculares, diabetes, insuficiencia renal, trastornos alimentarios y obesidad.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02004296 | 2002-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27689A1 true UY27689A1 (es) | 2003-08-29 |
Family
ID=27763338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27689A UY27689A1 (es) | 2002-02-28 | 2003-02-27 | Nuevos derivados de tiazol como antagonistas del receptor npy |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6686381B2 (es) |
| EP (1) | EP1480976B1 (es) |
| JP (1) | JP2005526732A (es) |
| KR (1) | KR100611854B1 (es) |
| CN (1) | CN100363362C (es) |
| AR (1) | AR038704A1 (es) |
| AT (1) | ATE373654T1 (es) |
| AU (1) | AU2003210305B2 (es) |
| BR (1) | BR0308108A (es) |
| CA (1) | CA2475299A1 (es) |
| DE (1) | DE60316411T2 (es) |
| ES (1) | ES2292992T3 (es) |
| GT (1) | GT200300045A (es) |
| MX (1) | MXPA04008379A (es) |
| PA (1) | PA8567301A1 (es) |
| PE (1) | PE20030930A1 (es) |
| PL (1) | PL372463A1 (es) |
| RU (1) | RU2004129285A (es) |
| TW (1) | TW200403995A (es) |
| UY (1) | UY27689A1 (es) |
| WO (1) | WO2003072577A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| BRPI0413458A (pt) | 2003-08-12 | 2006-10-17 | Hoffmann La Roche | compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade |
| JP2007501823A (ja) | 2003-08-12 | 2007-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | ２−アミノ−５−ベンゾイルチアゾールなるｎｐｙアンタゴニスト |
| DE602004011394T2 (de) * | 2003-12-08 | 2009-01-08 | F. Hoffmann-La Roche Ag | Thiazolderivate |
| US7820704B2 (en) * | 2004-04-20 | 2010-10-26 | Transtech Pharma, Inc. | Substituted heteroaryl derivatives, compositions, and methods of use |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| WO2007084391A2 (en) * | 2006-01-18 | 2007-07-26 | Amgen Inc. | Thiazole compounds as protein kinase b ( pkb) inhibitors |
| WO2010098298A1 (ja) * | 2009-02-27 | 2010-09-02 | 塩野義製薬株式会社 | 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物 |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| JP7523351B2 (ja) | 2018-01-31 | 2024-07-26 | デシフェラ・ファーマシューティカルズ，エルエルシー | 肥満細胞症の治療のための併用療法 |
| JP2021512105A (ja) | 2018-01-31 | 2021-05-13 | デシフェラ・ファーマシューティカルズ，エルエルシー | 消化管間質腫瘍の治療のための併用療法 |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| NZ784949A (en) | 2019-08-12 | 2025-09-26 | Deciphera Pharmaceuticals Llc | Ripretinib for treating gastrointestinal stromal tumors |
| AU2020419197B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| NZ789199A (en) | 2019-12-30 | 2025-07-25 | Deciphera Pharmaceuticals Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| AUPN163795A0 (en) | 1995-03-10 | 1995-04-06 | DIPNALL, David | A device for extracting energy from moving water particles |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| TR200100471T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri içeren farmasötik bileşimler |
| AU759388B2 (en) | 1998-08-14 | 2003-04-10 | Cheplapharm Arzneimittel Gmbh | Pharmaceutical compositions containing lipase inhibitors and chitosan |
| US20010039275A1 (en) * | 2000-02-04 | 2001-11-08 | Bowler Andrew Neil | Use of 2,4-diaminothiazole derivatives |
| AU2001246494A1 (en) * | 2000-03-03 | 2001-09-12 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
| EP1417188A1 (en) * | 2001-08-03 | 2004-05-12 | Novo Nordisk A/S | Novel 2,4-diaminothiazole derivatives |
-
2003
- 2003-02-19 CN CNB03804823XA patent/CN100363362C/zh not_active Expired - Fee Related
- 2003-02-19 PL PL03372463A patent/PL372463A1/xx not_active Application Discontinuation
- 2003-02-19 WO PCT/EP2003/001667 patent/WO2003072577A1/en not_active Ceased
- 2003-02-19 AT AT03742945T patent/ATE373654T1/de not_active IP Right Cessation
- 2003-02-19 RU RU2004129285/04A patent/RU2004129285A/ru not_active Application Discontinuation
- 2003-02-19 AU AU2003210305A patent/AU2003210305B2/en not_active Ceased
- 2003-02-19 MX MXPA04008379A patent/MXPA04008379A/es active IP Right Grant
- 2003-02-19 KR KR1020047013315A patent/KR100611854B1/ko not_active Expired - Fee Related
- 2003-02-19 CA CA002475299A patent/CA2475299A1/en not_active Abandoned
- 2003-02-19 BR BR0308108-7A patent/BR0308108A/pt not_active IP Right Cessation
- 2003-02-19 JP JP2003571283A patent/JP2005526732A/ja active Pending
- 2003-02-19 ES ES03742945T patent/ES2292992T3/es not_active Expired - Lifetime
- 2003-02-19 EP EP03742945A patent/EP1480976B1/en not_active Expired - Lifetime
- 2003-02-19 DE DE60316411T patent/DE60316411T2/de not_active Expired - Fee Related
- 2003-02-25 PE PE2003000182A patent/PE20030930A1/es not_active Application Discontinuation
- 2003-02-25 PA PA20038567301A patent/PA8567301A1/es unknown
- 2003-02-26 TW TW092104045A patent/TW200403995A/zh unknown
- 2003-02-26 GT GT200300045A patent/GT200300045A/es unknown
- 2003-02-26 US US10/374,573 patent/US6686381B2/en not_active Expired - Fee Related
- 2003-02-26 AR ARP030100627A patent/AR038704A1/es not_active Application Discontinuation
- 2003-02-27 UY UY27689A patent/UY27689A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US6686381B2 (en) | 2004-02-03 |
| GT200300045A (es) | 2003-09-23 |
| MXPA04008379A (es) | 2004-11-26 |
| PA8567301A1 (es) | 2004-02-07 |
| RU2004129285A (ru) | 2005-10-27 |
| CN100363362C (zh) | 2008-01-23 |
| AU2003210305B2 (en) | 2006-07-06 |
| TW200403995A (en) | 2004-03-16 |
| PE20030930A1 (es) | 2003-11-08 |
| CN1639158A (zh) | 2005-07-13 |
| KR100611854B1 (ko) | 2006-08-11 |
| WO2003072577A1 (en) | 2003-09-04 |
| EP1480976B1 (en) | 2007-09-19 |
| DE60316411T2 (de) | 2008-06-12 |
| CA2475299A1 (en) | 2003-09-04 |
| PL372463A1 (en) | 2005-07-25 |
| DE60316411D1 (de) | 2007-10-31 |
| BR0308108A (pt) | 2004-12-07 |
| US20030225141A1 (en) | 2003-12-04 |
| ATE373654T1 (de) | 2007-10-15 |
| AR038704A1 (es) | 2005-01-26 |
| AU2003210305A1 (en) | 2003-09-09 |
| KR20040094735A (ko) | 2004-11-10 |
| EP1480976A1 (en) | 2004-12-01 |
| ES2292992T3 (es) | 2008-03-16 |
| JP2005526732A (ja) | 2005-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8528401A1 (es) | Derivados de quinolina y quinazolina | |
| UY27689A1 (es) | Nuevos derivados de tiazol como antagonistas del receptor npy | |
| UY27462A1 (es) | Derivados de quinolina | |
| UY27646A1 (es) | Derivados de quinolina como antagonistas de npt | |
| UY27300A1 (es) | Nuevos derivados de quinolina | |
| CO6480932A2 (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida. | |
| CY1121853T1 (el) | Συνδυαστικη θεραπεια για την αγωγη του διαβητη | |
| UA85597C2 (ru) | Четвертичные соли как антагонисты ccr2 | |
| MY148108A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| ATE493386T1 (de) | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate | |
| MX2007003793A (es) | Antagonistas del receptor 2 de citocina quimioatrayente de dipiperidina sustituida. | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| HN2005000255A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
| EP1508570A4 (en) | NEW PHYSIOLOGICAL ACTIVE SUBSTANCES | |
| NO20070213L (no) | Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser | |
| MX336881B (es) | Compuestos heterociclicos triciclicos. | |
| DK1856090T3 (da) | Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
| WO2009134574A3 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| MX2010006204A (es) | Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| UY27018A1 (es) | Derivados de la pirimidina | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
| DE502004011919D1 (de) | -trien-3-yl sulfamate | |
| UY27883A1 (es) | Derivados de quinazolina | |
| EA200501565A1 (ru) | Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса | |
| UY31035A1 (es) | Utilizacion de 4-ciclopropilmetoxi-n-(3,5)-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20150126 |